ER+/PR+ breast cancer is a subtype of ER positive breast cancer where the tumor cells express both estrogen receptors (ER) and progesterone receptors (PR) on the surface. As the most common type of ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

Imlunestrant is approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, showing improved progression-free survival with abemaciclib. The oral administration of ...

Vepdegestrant significantly improved progression-free survival in ESR1-mutant ER-positive, HER2-negative advanced breast cancer compared to Faslodex, with a median of 5.0 months versus 2.1 months. The ...

A new therapy is effective against ER-positive, HER2-negative breast cancers, the most common subtype, according to a clinical trial. “These results will change how many breast cancers are treated,” ...

BOSTON — The risk for local recurrence of breast cancer decreases as event-free survival lengthens, according to an analysis of a large database from the Netherlands. The study, which also ...

The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...

The presence of the progesterone receptor marks this tumor as hormone-responsive and indicates that hormone therapy should be considered as a component of her adjuvant therapy. In some breast cancer ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...